Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, United Kingdom; Faculty of Medicine, University of Porto, Porto, Portugal.
Liver Transpl. 2013 Oct;19(10):1065-77. doi: 10.1002/lt.23704. Epub 2013 Aug 13.
Liver transplantation (LT) is an effective treatment for patients with end-stage autoimmune liver diseases such as primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis. Indications for LT for these diseases do not differ substantially from those used for other acute or chronic liver diseases. Despite the good outcomes reported, the recurrence of autoimmune liver disease is relatively common in the allograft. In addition, it has become apparent that autoimmunity and autoimmune liver disease can arise de novo after transplantation for nonautoimmune liver disorders. An awareness of the existence of recurrent autoimmune liver diseases and de novo autoimmune hepatitis after LT has important clinical implications because their management differs from the standard antirejection treatment and is similar to the management of classic autoimmune liver diseases in the native liver.
肝移植（LT）是治疗终末期自身免疫性肝病的有效方法，如原发性胆汁性肝硬化、原发性硬化性胆管炎和自身免疫性肝炎。这些疾病进行 LT 的适应证与其他急性或慢性肝病没有显著差异。尽管报告的结果良好，但同种异体移植物中自身免疫性肝病的复发相对常见。此外，人们已经意识到，在非自身免疫性肝病进行移植后，也会新出现自身免疫和自身免疫性肝病。LT 后对复发的自身免疫性肝病和新出现的自身免疫性肝炎的认识具有重要的临床意义，因为它们的治疗与标准的抗排斥治疗不同，与在原肝中治疗经典自身免疫性肝病相似。
